Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia
Join Us for November’s Brown Bag Webinar – Unraveling the Mysteries of Dreams & Nightmares in Narcolepsy
Avadel Pharmaceuticals Announces FDA Approval of LUMRYZ™ (sodium oxybate) ExtendedRelease Oral Suspension (CIII) for the Treatment of Cataplexy or Excessive Daytime Sleepiness in Patients 7 Years of Age and Older with Narcolepsy
Inaugural NYC Event Raises Nearly Half a Million Dollars to Support Narcolepsy Research, Awareness and Education